Trial · NCT07900373
Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
NCT07900373, Phase 3, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia. Trials, record NCT07900373. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900373
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
- NCT number
- NCT07900373
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 416 participants, estimated
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Conditions
- Pneumocystis Jirovecii Pneumonia
- Interventions
- Echinocandins, Placebo (0.9% Sodium chloride) infusion
- First posted
- 2026-10-28
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hierarchical Composite Clinical Outcome Assessed Using the Win Odds/Win Ratio | Day 30 | Hierarchical composite of death, new extracorporeal membrane oxygenation (ECMO), new invasive mechanical ventilation, CTCAE grade 4 adverse drug reactions considered at least probably related to treatment, new non-invasive ventilation, change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction, and hospital length of stay among survivors. Assessed using the Win Odds approach. |
| Secondary | Proportion of participants who died | Through Day 30 | Proportion of participants who died |
| Secondary | Hospital length of stay among survivors | Through Day 30 | Length of hospital stay among participants who survive. |
| Secondary | CTCAE grade 3 and 4 adverse drug reactions | Through Day 30 | Proportion of participants with CTCAE grade 3 or 4 adverse drug reactions considered at least probably related to treatment, by organ system. |
| Secondary | Time to occurrence of primary outcome components | Through Day 30 | Time to each component of the primary outcome, including death, new respiratory support, treatment changes, and severe adverse drug reactions. |
| Secondary | Proportion of patients requiring new ECMO | Through Day 30 | Proportion of patients requiring new extracorporeal membrane oxygenation |
| Secondary | Proportion of patients requiring new mechanical ventilation | Through Day 30 | Proportion of patients requiring new mechanical ventilation |
| Secondary | Proportion of patients with CTCAE grade 4 adverse drug reactions considered at least probably related to treatment | Through day 30 | Proportion of patients with CTCAE grade 4 adverse drug reactions considered at least probably related to treatment |
| Secondary | Proportion of patients requiring new non-invasive ventilation, | Through day 30 | Proportion of patients requiring new non-invasive ventilation, |
| Secondary | Proportion of patients with change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction | Through day 30 | Proportion of patients with change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900373
GET https://conductscience.org/api/trials/v1/NCT07900373/registered